Introduction {#Sec1}
============

Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent psychiatric disorders of childhood \[[@CR1]\] and is increasingly recognized as a condition that can persist into adulthood \[[@CR2], [@CR3]\]. The International Classification of Diseases, 10th Revision (ICD-10) \[[@CR4]\], Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) \[[@CR5]\] and DSM, 5th edition (DSM-5) \[[@CR6]\] diagnostic criteria for ADHD all require not only the presence of symptoms, but also evidence of significant impairment in social, academic or occupational functioning. The motivation for seeking medical attention is typically the impact on an individual's behaviour in daily life in domains such as educational achievement and relations with teachers, family and peers \[[@CR7]\]. Therefore, in addition to symptomatic relief, important goals in the treatment of ADHD are to improve health-related quality of life (HRQL) and to reduce functional impairment \[[@CR8]--[@CR10]\].

European and North American guidelines for the treatment of ADHD in children and adolescents recommend stimulants as part of a multimodal treatment plan incorporating psychoeducational, behavioural and/or other psychosocial interventions \[[@CR11]--[@CR18]\]. Lisdexamfetamine dimesylate (LDX) is the first and only stimulant prodrug. Long-acting amfetamine-based medications, including LDX, are an established front-line treatment option in North America for children, adolescents and adults with ADHD. In Europe, LDX is the only long-acting amfetamine-based medication with marketing authorization (in select countries) for the treatment of ADHD, where it is indicated in children and adolescents when response to previous methylphenidate is considered inadequate. A series of US-based, phase III clinical trials in children (aged 6--12 years) \[[@CR19]\], adolescents (aged 13--17 years) \[[@CR20]\] and adults (aged 18--55 years) \[[@CR21]\] demonstrated that LDX is an effective and generally well-tolerated treatment for the symptoms of ADHD. Therapeutic benefits in simulated school or workplace environments were sustained for at least 13 h in children \[[@CR22]\] and 14 h in adults \[[@CR23]\] following an early-morning dose of LDX. More recently, a pivotal, double-blind, placebo-controlled phase III trial (study SPD489-325) investigated the efficacy and safety of LDX in children and adolescents with ADHD in Europe \[[@CR24]\]. In this 7-week study, patients receiving LDX or the reference treatment (osmotic-release oral system methylphenidate; OROS-MPH) showed statistically significantly greater improvements in symptoms than those receiving placebo (*p* \< 0.001), as assessed using the ADHD Rating Scale IV (ADHD-RS-IV), with effect sizes of 1.80 and 1.26, respectively (primary efficacy outcome). On the Clinical Global Impressions-Improvement (CGI-I) scale, 78 % of patients in the LDX group and 61 % of those in the OROS-MPH group scored 1 ('very much improved') or 2 ('much improved'), compared with 14 % in the placebo group (*p* \< 0.001 for both active treatments).

We now report HRQL and functional impairment outcomes from study SPD489-325, as assessed using the Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) and the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P), respectively. The CHIP-CE:PRF is a generic, paediatric HRQL instrument with established validity and reliability in ADHD \[[@CR25]\]. It measures overall health status, including emotional and physical well-being, behaviour, performance and involvement with family and peers. The WFIRS-P is an ADHD-specific instrument with demonstrated sensitivity \[[@CR26], [@CR27]\], and addresses domains of daily functioning that are likely to be impaired in ADHD. Assessing the impact of LDX compared with placebo on HRQL and functional impairment were pre-specified secondary objectives of the study.

Methods {#Sec2}
=======

The study procedures of this randomized, double-blind, parallel-group, dose-optimized, placebo-controlled, phase III trial have been described previously \[[@CR24]\]. Study SPD489-325 (ClinicalTrials.gov identifier: NCT00763971) was conducted in accordance with current applicable regulations, the International Conference on Harmonisation of Good Clinical Practice, local ethical and legal requirements, and the Declaration of Helsinki (including its amendments). The study protocol was approved by an independent ethics committee/institutional review board and regulatory agency in each centre (as appropriate) before study initiation. Each patient's parent or legal guardian provided written, informed consent, and assent was obtained from each participant (as applicable) before commencing study-related procedures. The study took place between November 2008 and March 2011 \[[@CR24]\].

Study Population {#Sec3}
----------------

The study was conducted in 48 centres in ten European countries, and enrolled male and female children (aged 6--12 years) and adolescents (aged 13--17 years) who met DSM-IV-TR \[[@CR5]\] criteria for a primary diagnosis of ADHD. Eligible patients had an investigator-rated ADHD-RS-IV total score of 28 or higher at baseline, indicating symptoms of at least moderate severity. Key exclusion criteria included failure to respond to a previous course of OROS-MPH (but not of other formulations of methylphenidate) and the presence of a comorbid psychiatric diagnosis with significant symptoms (not including oppositional defiant disorder). Patients whose current ADHD medication provided effective control of symptoms with acceptable tolerability were also excluded. Enrolment was stratified such that adolescents comprised approximately 25 % of the study population.

Study Drug Administration {#Sec4}
-------------------------

Eligible patients completed a screening and washout period (up to 6 weeks) and were randomized (1:1:1) to receive once-daily LDX, placebo or the reference treatment (OROS-MPH). Randomization was stratified by country and age group (6--12 years of age or 13--17 years of age). Details of randomization and blinding have been previously described \[[@CR24]\]. As shown in Fig. [1](#Fig1){ref-type="fig"}, the 7-week, double-blind evaluation period consisted of a 4-week dose-optimization period (visits 1--3) and a 3-week dose-maintenance period (visits 4--7), followed by a 1-week washout and safety follow-up (visit 8).Fig. 1SPD489-325 study design. ^a^Screening and washout (visit −1) was conducted up to 6 weeks before baseline visit (week 0). At visits 1--3 (weeks 1--3), doses were titrated in the indicated single steps to achieve optimal tolerability and efficacy. From visit 4 onwards, doses could not be altered. Child Health and Illness Profile-Child Edition: Parent Report Form and Weiss Functional Impairment Rating Scale-Parent Report assessments were performed at baseline, and then at visits 4 and 7 (shown *boxed*) and/or at an early termination visit attended by patients who discontinued the trial. *LDX* lisdexamfetamine dimesylate, *OROS-MPH* osmotic-release oral system methylphenidate

Dose optimization to LDX 30, 50 or 70 mg daily, or to OROS-MPH 18, 36 or 54 mg daily (54 mg being the maximum OROS-MPH dose approved in Europe) was based on achieving an 'acceptable response', defined as a reduction of at least 30 % in ADHD-RS-IV total score from baseline and a CGI-I rating of 1 ('very much improved') or 2 ('much improved'), with tolerable side effects. Instructions were that study drugs should be taken daily upon wakening at approximately 0700 hours, beginning on the day after completion of the baseline visit (visit 0). Patients initially received LDX 30 mg daily, OROS-MPH 18 mg daily or placebo. If an acceptable response was not achieved, doses were increased in 20 mg (LDX) or 18 mg (OROS-MPH) steps at weekly intervals. One dose reduction was permitted if a patient experienced unacceptable tolerability. After visit 3, the dose could not be changed: participants unable to tolerate the study drug after this point were withdrawn from the study and attended an early termination visit. Patients who achieved an acceptable response continued on their optimal dose for the remainder of the double-blind evaluation period (visits 4--7) \[Fig. [1](#Fig1){ref-type="fig"}\].

It should be noted that the reference arm included OROS-MPH as an active control and not as a comparator. An active control is an established treatment known to be superior to placebo. The purpose of the reference arm is to facilitate interpretation of the study, especially in the case of an apparently negative outcome in the experimental arm. The study was neither designed nor statistically powered for comparison of the test drug with the reference treatment. Although this does not preclude post hoc analysis, statistical comparisons of LDX with OROS-MPH are not presented here.

HRQL Measure: Child Health and Illness Profile-Child Edition: Parent Report Form (CHIP-CE:PRF) {#Sec5}
----------------------------------------------------------------------------------------------

The CHIP-CE:PRF questionnaire comprises 76 items classed into five domains and 12 associated subdomains. Most items relate to the past 4 weeks; the remainder are not associated with a specific time period. Parents use a 5-point response format to assess each item. Data were handled according to the CHIP-CE Technical Manual \[[@CR28]\]. Domain and subdomain scores were the mean of the appropriate individual item scores (omitting items with a missing score). For a domain or subdomain score to be valid, no more than 30 % of the applicable items could be missing. The domain and subdomain scores were standardized to *T*-scores with a mean of 50 and a standard deviation (SD) of 10, using an algorithm based on normative sample data from the US \[[@CR29]\]. Higher CHIP-CE:PRF *T*-scores indicate better HRQL. The CHIP-CE:PRF Achievement domain was pre-specified as the primary HRQL measure.

Functional Measure: Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) {#Sec6}
------------------------------------------------------------------------------------

The WFIRS-P questionnaire comprises 50 items grouped into six domains. The items relate to the past month and are scored using a 4-point Likert scale: 0 (never or not at all); 1 (sometimes or somewhat); 2 (often or much); or 3 (very often or very much) \[[@CR30], [@CR31]\]. The WFIRS-P domain scores for each patient were the mean of the items in each domain, or of all the items for total score, omitting items with a missing or 'not applicable' score. WFIRS-P domain or total scores were considered invalid if more than 30 % of the item scores used for calculation were missing or 'not applicable' (with the exception of one question relating to siblings, for which a score of 'not applicable' could contribute to the minimum number of items). Higher WFIRS-P scores indicate more severe functional impairment.

Schedule of CHIP-CE:PRF and WFIRS-P Assessments {#Sec7}
-----------------------------------------------

A parent (or legally authorized representative) completed the CHIP-CE:PRF and WFIRS-P questionnaires at baseline (visit 0), then at visits 4 and 7 (weeks 4 and 7) and/or at early termination (Fig. [1](#Fig1){ref-type="fig"}). Visit 4 (week 4) assessments were introduced via a protocol amendment after study initiation and therefore were not conducted for all participants. Endpoint was defined as the last on-treatment visit (including early termination) at which a valid CHIP-CE:PRF domain or subdomain score, or valid WFIRS-P domain or total score, was obtained.

Statistical Analyses {#Sec8}
--------------------

All analyses were based on the full analysis set, defined as patients who were randomized and took at least one dose of study drug, but excluding patients from one site (*n* = 15) where there were violations of good clinical practice. Sample sizes were determined as previously described \[[@CR24]\]. To assess statistically the effect of treatment with either LDX or OROS-MPH versus placebo, analysis of covariance models were applied to the change in CHIP-CE:PRF domain and subdomain *T*-scores and to the change in WFIRS-P total and domain scores. The analyses included treatment group as the effect of interest (evaluated at a significance level of 0.05), the corresponding baseline score as covariate, and country and age group as blocking factors. The outputs (based on type III sum of squares) were the least-squares (LS) mean changes from baseline for each treatment group and the difference in these LS means between each drug treatment group and placebo. Effect sizes were calculated as the difference in LS means between each active drug and placebo, divided by the root-mean-square error. Conventionally, effect sizes of 0.2, 0.5 and 0.8 calculated by this method are operationally defined as small, medium and large, respectively \[[@CR32]\]. Results were analysed using SAS^®^ Version 9.1.3 or higher (SAS Institute Inc., Cary, NC, USA).

Results {#Sec9}
=======

Patient Disposition and Baseline Characteristics {#Sec10}
------------------------------------------------

As described previously \[[@CR24]\], 336 patients were randomized (LDX, *n* = 113; placebo, *n* = 111; OROS-MPH, *n* = 112) and 196 of these completed the study. Baseline demographics and disease characteristics were similar across treatment groups \[[@CR24]\]. The full analysis set comprised 317 patients (LDX, *n* = 104; placebo, *n* = 106; OROS-MPH, *n* = 107). The mean age of these patients was 10.9 years (SD 2.70 years) and 72.2 % were children (aged ≤12 years). The number of participants in the full analysis set who completed the trial were LDX, *n* = 77; placebo, *n* = 42; OROS-MPH, *n* = 72. The principal reason for study discontinuation was lack of efficacy, which was reported in 48.6 % of randomized patients in the placebo group, 19.6 % in the OROS-MPH group and 9.7 % in the LDX group \[[@CR24]\].

CHIP-CE:PRF {#Sec11}
-----------

### Baseline *T*-Scores {#Sec12}

At baseline, mean *T*-scores for all domains and subdomains were similar across groups (Table [1](#Tab1){ref-type="table"}). The lowest mean domain *T*-scores at baseline were almost two population SDs (i.e. 20 points) below the normative mean (50 points), and were observed in the Achievement domain (range 30.1--31.2), which was pre-specified as the primary HRQL outcome in the study. Within the Achievement domain, mean *T*-scores were lower in the Academic Performance subdomain than in the Peer Relations subdomain. Mean *T*-scores at baseline were also below 40 (i.e. 1 SD below the normative mean) for all treatment groups in the Risk Avoidance, Resilience and Satisfaction domains. In contrast, mean Comfort domain *T*-scores were closer to the normative mean of 50. The corresponding median *T*-scores and ranges are provided in the electronic supplementary material, Table A.Table 1Mean (SD) CHIP-CE:PRF domain and subdomain *T*-scores at baseline and endpointBaselineEndpointLDXPlaceboOROS-MPHLDXPlaceboOROS-MPH**Achievement**30.9 (9.71)30.1 (9.37)31.2 (10.19)40.3 (10.54)29.3 (10.06)37.7 (11.20)Academic Performance30.3 (10.18)29.4 (9.24)30.5 (9.28)40.7 (11.24)28.4 (10.89)36.9 (11.25)Peer Relations38.6 (14.56)39.2 (11.99)38.9 (14.00)42.3 (14.31)38.9 (12.92)43.8 (12.61)**Risk Avoidance**34.7 (13.72)31.6 (11.57)31.4 (11.59)44.6 (11.15)32.8 (12.63)40.6 (12.08)Individual Risk Avoidance41.0 (15.32)40.2 (12.47)37.5 (13.76)49.8 (12.77)41.6 (14.06)44.4 (13.47)Threats to Achievement34.3 (13.37)30.6 (11.60)31.4 (11.16)43.1 (10.51)31.8 (11.96)40.1 (11.62)**Resilience**37.5 (13.16)36.6 (11.45)35.5 (11.23)42.2 (11.43)37.3 (12.89)40.1 (12.40)Family Involvement40.6 (11.90)39.7 (11.06)39.6 (12.03)42.8 (10.78)38.2 (13.13)42.3 (11.72)Physical Activity46.0 (13.04)46.4 (12.33)46.7 (10.97)47.2 (11.24)47.8 (11.92)47.1 (10.36)Social Problem-Solving38.2 (13.45)36.8 (12.75)34.5 (12.13)44.2 (12.33)38.4 (13.57)40.8 (14.24)**Satisfaction**35.2 (14.93)34.4 (14.27)36.2 (13.82)39.5 (14.14)36.1 (13.55)40.2 (12.99)Satisfaction with Health41.2 (13.86)40.5 (13.66)41.4 (13.56)44.2 (12.63)41.7 (14.42)43.8 (12.62)Satisfaction with Self32.3 (15.75)31.5 (15.58)33.9 (13.70)36.7 (14.94)33.5 (13.60)38.6 (12.59)**Comfort**44.0 (12.55)43.0 (11.77)44.5 (9.50)46.8 (12.59)46.5 (10.44)48.1 (9.70)Physical Comfort50.3 (10.53)50.9 (10.51)52.7 (8.82)52.0 (9.18)53.6 (8.43)53.2 (9.34)Emotional Comfort39.3 (14.11)37.2 (12.47)38.4 (11.31)42.7 (14.90)39.7 (12.55)43.0 (10.83)Restricted Activity49.3 (9.93)48.5 (12.49)49.0 (10.06)50.5 (8.51)52.2 (7.68)52.0 (7.92)Domains are shown in bold and subdomains in normal type. Higher scores indicate better health-related quality of life*CHIP-CE:PRF* Child Health and Illness Profile-Child Edition: Parent Report Form, *LDX* lisdexamfetamine dimesylate, *OROS-MPH* osmotic-release oral system methylphenidate, *SD* standard deviation

### Placebo-Adjusted Changes at Endpoint {#Sec13}

In the LDX treatment group, the change in Achievement domain *T*-score from baseline to endpoint was statistically significantly greater than in the placebo group (effect size 1.280; *p* \< 0.001) \[Fig. [2](#Fig2){ref-type="fig"}\]. Ranked by decreasing effect size, statistically significant improvements in *T*-scores compared with placebo were also observed in the Risk Avoidance (1.079; *p* \< 0.001), Resilience (0.421; *p* \< 0.01) and Satisfaction (0.365; *p* \< 0.05) domains. Within these domains, there were statistically significant improvements in all subdomains except Physical Activity and Satisfaction with Self. Compared with placebo, there were no statistically significant changes in the Comfort domain or any of its subdomains in the LDX treatment group (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Placebo-adjusted changes in CHIP-CE:PRF domain and subdomain *T*-scores from baseline to endpoint. *Histogram* shows the LS mean change from baseline to endpoint in CHIP-CE:PRF domain and subdomain *T*-scores for the LDX and OROS-MPH groups after subtraction of placebo values. *Error bars* show 95 % confidence intervals. Effect size is the difference in LS mean divided by root-mean-square error. Positive differences indicate improvement compared with placebo. *CHIP-CE:PRF* Child Health and Illness Profile-Child Edition: Parent Report Form, *LDX* lisdexamfetamine dimesylate, *LS* least-squares, *OROS-MPH* osmotic-release oral system methylphenidate. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs placebo

In the OROS-MPH reference arm, changes from baseline to endpoint were also statistically significantly greater than in the placebo group in the Achievement domain (effect size 0.912; *p* \< 0.001) \[Fig. [2](#Fig2){ref-type="fig"}\]. Ranked by decreasing effect size, statistically significant improvements in *T*-scores compared with placebo were also observed in the Risk Avoidance (0.948; *p* \< 0.001), Resilience (0.398; *p* \< 0.05) and Satisfaction (0.349; *p* \< 0.05) domains. Within these domains, statistically significant improvements were observed in all subdomains except Physical Activity and Satisfaction with Health. Compared with placebo, there were no statistically significant changes in the Comfort domain or any of its subdomains in the OROS-MPH reference arm (Fig. [2](#Fig2){ref-type="fig"}).

### Changes from Baseline to Week 4, Week 7 and Endpoint {#Sec14}

In both active treatment groups, there were statistically significant improvements from baseline by week 4 in the Achievement and Risk Avoidance domains, and by week 7 in these and all other domains (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Changes in CHIP-CE:PRF domain *T*-scores from baseline to study week 4, 7 and endpoint. *Circles* indicate the LS mean change from baseline in *T*-scores in the indicated CHIP-CE:PRF domains for the **a** LDX, **b** OROS-MPH or **c** placebo groups. *Error bars* show 95 % confidence intervals. Numbers of observations (*n*) are shown for each data point. Positive differences indicate improvement compared with placebo. *BL* baseline, *CHIP-CE:PRF* Child Health and Illness Profile-Child Edition: Parent Report Form, *EP* endpoint, *LDX* lisdexamfetamine dimesylate, *LS* least-squares, *OROS-MPH* osmotic-release oral system methylphenidate, *W4* week 4, *W7* week 7. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs baseline

WFIRS-P {#Sec15}
-------

### Baseline Scores {#Sec16}

At baseline, mean scores for each of the six WFIRS-P domains were similar across treatment groups, with the highest scores (greatest impairment) observed in the Family domain and the Learning and School domain (Table [2](#Tab2){ref-type="table"}). The corresponding median scores and ranges are provided in the electronic supplementary material, Table B.Table 2Mean (SD) WFIRS-P domain and total scores at study baseline and endpointBaselineEndpointLDXPlaceboOROS-MPHLDXPlaceboOROS-MPHFamily1.27 (0.731)1.40 (0.766)1.40 (0.757)0.95 (0.760)1.40 (0.794)1.07 (0.769)Learning and School1.24 (0.647)1.31 (0.614)1.23 (0.604)0.66 (0.512)1.26 (0.600)0.82 (0.561)Life Skills1.05 (0.475)1.15 (0.530)1.09 (0.486)0.89 (0.541)1.04 (0.484)0.88 (0.456)Child's Self-Concept1.05 (0.878)1.09 (0.781)1.00 (0.747)0.83 (0.840)1.00 (0.825)0.73 (0.757)Social Activities1.02 (0.679)1.06 (0.613)1.01 (0.651)0.76 (0.613)1.04 (0.662)0.77 (0.582)Risky Activities0.49 (0.379)0.54 (0.376)0.59 (0.411)0.28 (0.319)0.49 (0.388)0.41 (0.378)Total1.01 (0.454)1.10 (0.456)1.07 (0.437)0.71 (0.450)1.04 (0.467)0.79 (0.441)Higher scores indicate more severe functional impairment*LDX* lisdexamfetamine dimesylate, *OROS-MPH* osmotic-release oral system methylphenidate, *SD* standard deviation, *WFIRS-P* Weiss Functional Impairment Ratings Scale-Parent Report

### Placebo-Adjusted Changes at Endpoint {#Sec17}

In the LDX treatment group, the change in WFIRS-P total score from baseline to endpoint was statistically significantly greater than in the placebo group (effect size 0.924; *p* \< 0.001) \[Fig. [4](#Fig4){ref-type="fig"}\]. Statistically significant improvements in scores compared with placebo were observed in the Learning and School, Family, Social Activities and Risky Activities domains (*p* \< 0.001).Fig. 4Placebo-adjusted changes in WFIRS-P domain and total scores from baseline to endpoint. *Histogram* shows the LS mean change from baseline to endpoint in WFIRS-P domain and total scores for the LDX and OROS-MPH groups after subtraction of placebo values. *Error bars* show 95 % confidence intervals. Effect size is the difference in LS mean divided by root-mean-square error. Negative differences indicate improvement compared with placebo. *LDX* lisdexamfetamine dimesylate, *LS* least-squares, *OROS-MPH* osmotic-release oral system methylphenidate, *WFIRS-P* Weiss Functional Impairment Ratings Scale-Parent Report. \**p* \< 0.05, \*\*\**p* \< 0.001 vs placebo

In the OROS-MPH reference arm, the change in WFIRS-P total score from baseline to endpoint was also statistically significantly greater than in the placebo group (effect size 0.772; *p* \< 0.001) \[Fig. [4](#Fig4){ref-type="fig"}\]. Statistically significant improvements in placebo-adjusted scores were observed in the same four WFIRS-P domains as for LDX, and also in the remaining two domains, Life Skills and Child's Self-Concept (*p* \< 0.05).

### Changes from Baseline to Week 4, Week 7 and Endpoint {#Sec18}

In the LDX group, statistically significant changes from baseline were observed by week 4 in WFIRS-P total score and the Learning and School, Social Activities and Risky Activities domains, and by week 7 in these and all other domains (Fig. [5](#Fig5){ref-type="fig"}). In the OROS-MPH group, statistically significant changes from baseline were observed by week 4 in WFIRS-P total score and the Learning and School and Risky Activities domains, and by week 7 in these and all other domains (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Change in WFIRS-P scores from baseline to study week 4, 7 and endpoint. *Circles* indicate the LS mean change from baseline in scores in the indicated WFIRS-P domain or total scores for **a** LDX, **b** OROS-MPH or **c** placebo groups. *Error bars* show 95 % confidence intervals. Numbers of observations (*n*) are shown for each data point. Negative differences indicate improvement compared with placebo. *BL* baseline, *EP* endpoint, *LDX* lisdexamfetamine dimesylate, *LS* least-squares, *OROS-MPH* osmotic-release oral system methylphenidate, *W4* week 4, *W7* week 7, *WFIRS-P* Weiss Functional Impairment Ratings Scale-Parent Report. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 vs baseline

Discussion {#Sec19}
==========

Optimal management of ADHD aims not only to ameliorate patients' symptoms, but also to improve HRQL and to reduce functional impairment, because these are often the main motivations for seeking treatment \[[@CR7], [@CR11]\]. We have previously reported improvements in investigator-rated ADHD symptoms, measured using the ADHD-RS-IV and CGI-I instruments, in children and adolescents treated with LDX in a European, 7-week, phase III trial (SPD489-325) \[[@CR24]\]. The present data show that LDX treatment also resulted in improvements in HRQL and functioning in this study, assessed using two parent-rated instruments, the CHIP-CE:PRF and WFIRS-P, respectively. The reference treatment, OROS-MPH, also resulted in improvements in scores on these instruments. In the CHIP-CE:PRF Achievement domain, which was pre-specified as the primary HRQL outcome, both LDX and OROS-MPH significantly improved mean *T*-scores versus placebo, with large effect sizes (1.280 and 0.912, respectively). Based on these data, the Summary of Product Characteristics, part of the European marketing authorization recently approved under the decentralized procedure, notes that LDX "showed significant improvement in child achievement in academic performance".

This is the first study of any stimulant treatment for ADHD to use the CHIP-CE:PRF. The reliability and validity of this generic, paediatric HRQL instrument in ADHD have been established in the prospective, pan-European ADORE (Attention Deficit Hyperactivity Disorder Observational Research in Europe) study, which included 1477 children and adolescents with ADHD in the analysis \[[@CR25]\], and have been confirmed in a combined analysis \[[@CR33]\] of baseline data from 794 patients aged 6--15 years in five atomoxetine trials \[[@CR33]--[@CR37]\]. Baseline CHIP-CE:PRF values in the present study were similar to values reported in both of these analyses: mean *T*-scores in the Achievement and Risk Avoidance domains were approximately 2 population SDs (20 points) below the US community normative mean (50 points); those in the Resilience and Satisfaction domains were at least 1 SD below the normative mean; and the mean *T*-score in the Comfort domain was within 1 SD of the normative mean. Together, the results of these studies indicate that untreated ADHD imposes a substantial burden of illness. This is reflected by substantial economic costs of the disorder to society \[[@CR38]\]. By comparison, in other studies using the CHIP in patient populations, mean standardized domain or subdomain *T*-scores were 1 SD or more below the normative mean in children undergoing the last phase of maintenance therapy for leukaemia \[[@CR39]\], but were within 1 SD of the normative mean in children and/or adolescents with chronic kidney disease \[[@CR40]--[@CR43]\] or asthma \[[@CR44], [@CR45]\].

The impact of LDX treatment was greatest in the Achievement domain of the CHIP-CE:PRF (effect size 1.280). Factor analyses of both the ADORE and combined atomoxetine study data have suggested that, unlike the subdomains of the other four CHIP-CE:PRF domains, the Academic Performance and Peer Relations subdomains of Achievement are distinct constructs in patients with ADHD \[[@CR25], [@CR33]\]. This may explain the difference between the effect sizes for LDX treatment observed in these subdomains (1.222 and 0.562, respectively). A robust treatment effect of LDX was also observed in the Risk Avoidance domain (effect size 1.079). Statistically significant placebo-adjusted LDX treatment effects were observed in the Resilience and Satisfaction domains, but not in the Comfort domain. At endpoint, mean *T*-scores for all CHIP-CE:PRF domains in the LDX treatment group were within approximately 1 SD of the normative mean. A similar pattern was observed in the OROS-MPH reference arm. Thus, in both active treatment arms, the greatest impact of stimulant pharmacotherapy was observed in the domains with the most profound deficits at baseline.

Improved HRQL in LDX-treated adults with ADHD was previously documented in a 4-week, open-label study employing the ADHD Impact Module for Adults. Methylphenidate and mixed amfetamine salts have also been reported to have a beneficial impact on HRQL measured using other instruments \[[@CR8], [@CR9]\]. The non-stimulant atomoxetine is the only other ADHD pharmacotherapy for which the impact on HRQL has been investigated using CHIP-CE:PRF. A meta-analysis of atomoxetine studies \[[@CR46]\] indicated that treatment benefits were most pronounced in the Achievement and Risk Avoidance domains, as in the present study. The effect sizes for atomoxetine in these domains (0.431 and 0.489, respectively, \[[@CR46]\]) were, however, somewhat smaller than those reported here for both LDX and OROS-MPH. Furthermore, unlike the stimulants investigated in the present study, atomoxetine did not statistically significantly affect scores in the Satisfaction and Resilience domains. These results suggest that earlier observations that stimulants are more effective than non-stimulants in reducing the symptoms of ADHD \[[@CR47]\] may extend to HRQL deficits, at least as measured using the CHIP-CE:PRF.

The WFIRS-P was designed to provide a more sensitive and meaningful measure of functional impairment in patients with ADHD than that provided by generic instruments. The instrument can also be used to define impairment for clinical diagnostic purposes. As an outcome measure, it also has good internal consistency and sensitivity to change, as well as moderate convergent validity with other instruments \[[@CR30]\]. However, published data for the WFIRS-P are limited \[[@CR26], [@CR27]\] and there are currently no published population norm data \[[@CR30]\]. In the present study, mean WFIRS-P total scores at baseline were approximately 1.0 on the Likert scale (which has a range of 0--3). Although this could be interpreted as modest impairment, it is important to note that these mean responses at the domain or total level do not capture dispersion, and are likely to conceal high individual item scores of potential clinical significance. The mean total scores at baseline exceed the optimal cut-off score (0.65) for differentiating children with and without ADHD, as derived by receiver-operating characteristics curve analysis in a multicentre, observational study (Hodgkins P, et al., personal communication). The effect sizes for placebo-adjusted changes from baseline to endpoint in WFIRS-P total score suggest that both active treatment effects were robust (LDX, 0.924; OROS-MPH, 0.772). As at baseline, the use of mean scores may not fully reflect treatment-induced improvements at the individual item level. In concordance with the CHIP-CE:PRF results, effect sizes were greatest in the WFIRS-P domains that were most impaired at baseline.

The interdependence of symptom severity, functioning and HRQL in ADHD is still uncertain and under exploration \[[@CR9]\]. A combined analysis of atomoxetine clinical trials found that correlations between CHIP-CE:PRF *T*-scores (total, domain and subdomain) and ADHD-RS-IV total score were low (mostly below 0.4) \[[@CR33]\]. Correlative analyses of the relevant outcome measures from the present study are awaited. However, effect sizes at endpoint were larger for ADHD-RS-IV total score (LDX, 1.80; OROS-MPH, 1.26) \[[@CR24]\] than for any domain of the CHIP-CE:PRF or WFIRS-P, supporting the notion that symptoms and HRQL or functioning are distinct, but related, constructs \[[@CR48]\]. Furthermore, while symptomatic benefits were evident as early as study week 1 \[[@CR24]\], some CHIP-CE:PRF and WFIRS-P domains did not show improvements until study week 7, suggesting that some aspects of HRQL and functioning may respond to stimulant medications over a longer treatment period than others. Also warranting further investigation, although modest and awaiting post hoc statistical analysis, are the differences between the two active treatments in effect sizes observed in some CHIP-CE:PRF and WFIRS-P domains, which may have implications for individualized treatment \[[@CR10]\].

The strengths of this study include its randomized, double-blind, placebo-controlled design, and the enrolment of both children and adolescents at multiple centres in Europe. Five principal limitations of the study design should, however, be considered when interpreting these results. First, the study population was enrolled according to stringent inclusion and exclusion criteria and so may not be typical of patients seen in general clinical practice. Second, dose optimization was designed to achieve balanced efficacy and tolerability, but precluded evaluation of whether the stimulant treatment effects were dose dependent and whether the LDX and OROS-MPH doses were equivalent. Third, the study was not designed or powered for direct comparison of the test drug (LDX) with the active control (OROS-MPH). Fourth, the short-term nature of the study does not permit evaluation of the long-term impact of LDX or OROS-MPH treatment on HRQL and functional outcomes. The results of SPD489-326, a follow-on study (with additional US patients) comprising open-label LDX treatment for at least 26 weeks, coupled to a subsequent 6-week, double-blind, parallel-group, placebo-controlled, randomized-withdrawal period, may provide insight in this regard. Finally, the majority of patients in the LDX and OROS-MPH groups completed the study, but the majority of patients in the placebo group left the study early.

The HRQL and functional impairment instruments selected for this study also present their own strengths and weaknesses. Parental proxy assessments overcome the issue of potentially unreliable self-rating by patients with ADHD, especially younger children, but may capture different aspects of HRQL and functioning compared with self-rated instruments. For consistency, participants of all ages were assessed using the same questionnaires, despite the availability of self-rated versions of the instruments for adolescents. The CHIP-CE:PRF *T*-scores are generated using algorithms based on a US reference population, and although the Spanish CHIP-CE:PRF reference population is very similar \[[@CR49], [@CR50]\], these community samples may not be representative of normative HRQL in Europe.

Conclusions {#Sec20}
===========

Once-daily, optimized doses of LDX and OROS-MPH were more effective than placebo in improving HRQL and functioning in children and adolescents with at least moderately symptomatic ADHD in this European, 7-week, phase III study. The effects were seen across multiple domains of the CHIP-CE:PRF and WFIRS-P instruments, including the key domains relating to achievement in school.
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